Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Donald

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Medicine Insights. Pathology|June 5, 2012
Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum SamplesShethah R Morgan, Jessica Whiteley, Emma Donald, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 8, 2010
A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samplesGillian Ellison, Emma Donald, Gael McWalter, et al.
Applied Bionics and Biomechanics|September 30, 2021
Joint Angle, Range of Motion, Force, and Moment Assessment: Responses of the Lower Limb to Ankle Plantarflexion and DorsiflexionUkadike Chris Ugbolue, Chloe Robson, Emma Donald, et al.
The Journal of Molecular Diagnostics : JMD|March 18, 2014
Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing systemKyaw L Aung, Emma Donald, Gillian Ellison, et al.
Breast Cancer Research and Treatment|January 29, 2010
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancerRuth E Board, Andrew M Wardley, J Michael Dixon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancerFred R Hirsch, Marileila Varella-Garcia, Paul A Bunn, et al.
BMC Cancer|April 17, 2015
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studiesAdam Platt, John Morten, Qunsheng Ji, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Medicine Insights. Pathology|June 5, 2012
Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum SamplesShethah R Morgan, Jessica Whiteley, Emma Donald, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 8, 2010
A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samplesGillian Ellison, Emma Donald, Gael McWalter, et al.
Applied Bionics and Biomechanics|September 30, 2021
Joint Angle, Range of Motion, Force, and Moment Assessment: Responses of the Lower Limb to Ankle Plantarflexion and DorsiflexionUkadike Chris Ugbolue, Chloe Robson, Emma Donald, et al.
The Journal of Molecular Diagnostics : JMD|March 18, 2014
Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing systemKyaw L Aung, Emma Donald, Gillian Ellison, et al.
Breast Cancer Research and Treatment|January 29, 2010
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancerRuth E Board, Andrew M Wardley, J Michael Dixon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancerFred R Hirsch, Marileila Varella-Garcia, Paul A Bunn, et al.
BMC Cancer|April 17, 2015
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studiesAdam Platt, John Morten, Qunsheng Ji, et al.
Pageof 1